Krebs Biochemicals (India) Performance
| KREBSBIO | 85.12 0.06 0.07% |
Krebs Biochemicals has a performance score of 2 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 0.77, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Krebs Biochemicals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Krebs Biochemicals is expected to be smaller as well. Krebs Biochemicals and right now secures a risk of 2.37%. Please verify Krebs Biochemicals and jensen alpha, skewness, relative strength index, as well as the relationship between the value at risk and day median price , to decide if Krebs Biochemicals and will be following its current price movements.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Krebs Biochemicals and are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite fairly strong fundamental drivers, Krebs Biochemicals is not utilizing all of its potentials. The latest stock price confusion, may contribute to short-horizon losses for the traders. ...more
Ex Dividend Date 2005-09-14 |
1 | Krebs Biochemicals Industries Ltd Announces Unaudited Standalone Financial Results for the Quarter and Audited Standalone Financial Results for the Fifteen Mont... | 08/26/2024 |
| Begin Period Cash Flow | 858 K |
Krebs |
Krebs Biochemicals Relative Risk vs. Return Landscape
If you would invest 8,225 in Krebs Biochemicals and on August 20, 2024 and sell it today you would earn a total of 287.00 from holding Krebs Biochemicals and or generate 3.49% return on investment over 90 days. Krebs Biochemicals and is generating 0.0817% of daily returns and assumes 2.3654% volatility on return distribution over the 90 days horizon. Simply put, 21% of stocks are less volatile than Krebs, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Krebs Biochemicals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Krebs Biochemicals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Krebs Biochemicals and, and traders can use it to determine the average amount a Krebs Biochemicals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0345
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | KREBSBIO | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.37 actual daily | 21 79% of assets are more volatile |
Expected Return
| 0.08 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Krebs Biochemicals is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Krebs Biochemicals by adding it to a well-diversified portfolio.
Krebs Biochemicals Fundamentals Growth
Krebs Stock prices reflect investors' perceptions of the future prospects and financial health of Krebs Biochemicals, and Krebs Biochemicals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Krebs Stock performance.
| Return On Asset | -0.0532 | ||||
| Profit Margin | (0.37) % | ||||
| Operating Margin | (0.30) % | ||||
| Current Valuation | 4.23 B | ||||
| Shares Outstanding | 21.56 M | ||||
| Price To Sales | 3.57 X | ||||
| Revenue | 504.21 M | ||||
| Gross Profit | 244.19 M | ||||
| EBITDA | (82.73 M) | ||||
| Net Income | (197.28 M) | ||||
| Cash And Equivalents | (1 K) | ||||
| Total Debt | 1.93 B | ||||
| Book Value Per Share | (55.29) X | ||||
| Cash Flow From Operations | 23.04 M | ||||
| Earnings Per Share | (9.09) X | ||||
| Total Asset | 1.78 B | ||||
| Retained Earnings | (2.7 B) | ||||
About Krebs Biochemicals Performance
By evaluating Krebs Biochemicals' fundamental ratios, stakeholders can gain valuable insights into Krebs Biochemicals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Krebs Biochemicals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Krebs Biochemicals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Krebs Biochemicals is entity of India. It is traded as Stock on NSE exchange.Things to note about Krebs Biochemicals and performance evaluation
Checking the ongoing alerts about Krebs Biochemicals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Krebs Biochemicals and help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the revenue of 504.21 M. Net Loss for the year was (197.28 M) with profit before overhead, payroll, taxes, and interest of 244.19 M. | |
| About 78.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Krebs Biochemicals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Krebs Biochemicals' stock is overvalued or undervalued compared to its peers.
- Examining Krebs Biochemicals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Krebs Biochemicals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Krebs Biochemicals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Krebs Biochemicals' stock. These opinions can provide insight into Krebs Biochemicals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Krebs Stock analysis
When running Krebs Biochemicals' price analysis, check to measure Krebs Biochemicals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krebs Biochemicals is operating at the current time. Most of Krebs Biochemicals' value examination focuses on studying past and present price action to predict the probability of Krebs Biochemicals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krebs Biochemicals' price. Additionally, you may evaluate how the addition of Krebs Biochemicals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |